+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying tirzepatide to understand its effects on weight loss and the development of type 2 diabetes in adults who have obesity but do not have diabetes. This phase 4 study takes place in a real-world setting and aims to compare tirzepatide to standard care for these adults who also have at least one health condition related to their weight. The study is sponsored by Eli Lilly and Company and includes participants who are registered patients at participating sites. Participants will be randomly assigned to receive either tirzepatide injections once weekly along with standard care or standard care alone. The study will last about 260 weeks approximately 5 years, allowing researchers to observe long-term effects. The main focus is on how much participants body weight changes from the start of the study after 24 months, as well as whether they develop type 2 diabetes or other health complications related to obesity over 60 months. Throughout the study, participants will have various health measurements taken, including weight, waist size, blood pressure, cholesterol levels, liver enzymes, and quality of life assessments. Researchers will track the time it takes for participants to develop type 2 diabetes and monitor changes in blood sugar control and other health markers. Participants health resource use and overall wellbeing will also be evaluated. These assessments help understand the impact of tirzepatide compared to standard care over the long term.

Age: 18Years +All GendersPhase 4
30 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations